关于生物药物的当前数据:评估喘中的临床缓解
Ian Pavord1, Rohit K Katial2, David J Jackson3
1University of Oxford, Oxford, United Kingdom.
The Journal of allergy and clinical immunology
|October 1, 2025
概括
生物疗法为严重喘患者提供了显著的改善,缓解率因研究而异. 需要进一步的研究来定义喘缓解和确定预测因素.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 生物疗法对严重喘有希望,导致人们对临床缓解有兴趣.
- 在接受生物药物治疗的严重喘成年人中,观察到的缓解率在研究中从13%到43%不等.
- 目前的缓解定义通常包括恶化,口服皮质类固醇使用,症状控制和肺功能.
研究的目的:
- 审查当前对接受生物治疗的患者临床喘缓解的理解.
- 强调前性研究的必要性,以改进缓解的定义,并确定相关的患者特征.
- 探索有关儿童群体喘缓解的当前知识状态.
主要方法:
- 对现实世界的回顾性研究和随机对照试验的后期分析进行审查.
- 对缓解标准的分析,重点关注一个共同的四个组成部分的定义.
- 综合有关患者因子与实现缓解相关的证据.
主要成果:
- 使用生物药物的成人喘缓解率有所不同 (19-43%的现实世界,13-35%的RCT).
- 2型炎症内型,较不严重的疾病,较短的持续时间和较少的并发症预测了缓解.
- 关于儿童和青少年使用生物药物缓解喘的数据有限.
结论:
- 生物疗法可以诱导严重喘的实质性和持久改善,显著的缓解率.
- 进一步的前性研究对于标准化喘缓解标准和确定关键预测因子至关重要.
- 了解儿科喘患者的缓解需要专门的调查.
相关概念视频
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K


